8. Adobe Inc. (NASDAQ:ADBE)
Adobe Inc. (NASDAQ:ADBE) ranks among the best high profit margin stocks to buy. On March 12, Adobe Inc. (NASDAQ:ADBE) posted strong fiscal Q1 earnings, though its stock price fell 6.7% owing to leadership transition news and fears about AI competition. Adobe’s results exceeded forecasts, with annualized recurring revenue of $26.06 billion and AI-driven revenue growth tripling year-over-year.
Moreover, the company’s AI shift has shown up in a number of major areas. During Q1, monthly active users across Acrobat, Creative Cloud, Express, and Firefly reached 850 million, representing a 17% increase year-over-year.
Despite the strong earnings announcement, Adobe Inc. (NASDAQ:ADBE) shares fell as CEO Shantanu Narayen announced his plan to leave Adobe after 18 years in the role. Narayen stated that he would collaborate with Lead Independent Director Frank Calderoni and the Board to select his successor, although no timetable was provided.
Adobe Inc. (NASDAQ:ADBE) is a software company that specializes in creating, publishing, and promoting digital content. It offers a wide range of tools for professionals and consumers, including Photoshop, Illustrator, Acrobat, and Premiere Pro, which are often bundled in the Adobe Creative Cloud subscription.
7. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) ranks among the best high profit margin stocks to buy. On March 10, Truist Securities boosted its price target for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) to $525 from $490, while keeping a Buy rating on the company’s shares. The firm cited encouraging Week-36 interim findings from Vertex’s Phase 3 RAINIER study in IgAN.
The trial satisfied all primary and secondary objectives, demonstrating deep, consistent answers across subgroups and a strong safety profile. The trial results are the first of several major catalysts for Vertex’s rare kidney lineup, which has recently gained investor attention.
Stifel, which has a Hold rating on VRTX shares, also remarked on the study’s findings, saying they are highly statistically relevant and should meet the clearance criteria. However, the firm stated that it is uncertain whether the medication differs from competing products such as Otsuka’s sibeprenlimab in the increasingly saturated IgAN market.
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is a global biotechnology company. It develops and commercializes therapies for serious diseases, with a primary focus on cystic fibrosis and genetic disorders.
